No Data
No Data
Capricor Reports Positive Long-term Data for DMD Drug Deramiocel
Morgan Stanley Adjusts Price Target on Vertex Pharmaceuticals to $473 From $474
Vertex Pharmaceuticals (VRTX) Receives a Hold From Morgan Stanley
7 Children Given Bluebird's Skysona Developed Blood Cancer: Study
Vertex to Announce Third Quarter 2024 Financial Results on November 4th
Raymond James Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating